quantisnow
FeedTopReportsPricing
⌘K
Live feed
21:00:06·44d
INSIDERFiling
ADMA Biologics Inc logo

President and CEO Grossman Adam S covered exercise/tax liability with 85,951 shares, decreasing direct ownership by 4% to 2,118,777 units (SEC Form 4)

ADMA· ADMA Biologics Inc
Health Care
Original source

Companies

  • ADMA
    ADMA Biologics Inc
    Health Care

Recent analyst ratings

  • Apr 21UpdateCanaccord Genuity$21.00
  • Mar 26UpdateCantor Fitzgerald-
  • Jul 19UpdateRaymond James$5.00
  • Oct 13UpdateMizuho$5.00
  • Nov 11UpdateRaymond James$5.00
  • Nov 9UpdateCantor Fitzgerald$4.50

Related

  • ANALYST2d
    Canaccord Genuity initiated coverage on ADMA Biologics with a new price target
  • SEC8d
    SEC Form DEFA14A filed by ADMA Biologics Inc
  • SEC8d
    SEC Form DEF 14A filed by ADMA Biologics Inc
  • INSIDER20d
    SEC Form 4 filed by Kestenberg-Messina Kaitlin M.
  • SEC27d
    ADMA Biologics Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
  • PR27d
    ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research
  • SEC28d
    Amendment: SEC Form SCHEDULE 13G/A filed by ADMA Biologics Inc
  • ANALYST28d
    ADMA Biologics downgraded by Cantor Fitzgerald
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022